Journal Article (Editorial)

DZNE-2021-00988

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive.

Ewers, M. (First author)DZNE* ; Ioannidis, J. P. A. ; Plesnila, N.Extern*

2021
Elsevier Science Amsterdam [u.a.]

This record in other databases:    

Please use a persistent id in citations: doi:10.1016/j.jclinepi.2020.10.008

Keyword(s): COVID-19 Drug Treatment (MeSH) ; COVID-19: drug therapy (MeSH) ; COVID-19: mortality (MeSH) ; Clinical Trials as Topic: standards (MeSH) ; Humans (MeSH) ; Hydroxychloroquine: adverse effects (MeSH) ; Hydroxychloroquine: therapeutic use (MeSH) ; Information Dissemination (MeSH) ; Medical Records (MeSH) ; Observational Studies as Topic: standards (MeSH) ; Open Access Publishing (MeSH) ; Survival Analysis (MeSH) ; Time Factors (MeSH) ; Hydroxychloroquine

---

Contributing Institute(s):

1. Molecular Neurobiology (AG Simons)

Research Program(s):

1. 351 - Brain Function (POF4-351) (POF4-351)

Appears in the scientific report 2021

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---